Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$59.69 USD
+1.19 (2.03%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $59.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 261 - 280 ( 311 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Life Sciences: Crowdsourcing AAN: Recap of R&R and Pharm3r Twitter Survey
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Life Sciences: Crowdsourcing AAN: Recap of R&R and Pharm3r Twitter Survey
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Encouraging Data Points for ''357 in ALS to Inform Registrational Path
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
''357 Receives EMA Orphan Status; Data Points in April
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Initiation of Phase I Trial of Oral Omecamtiv Indicative of AMGN''s Continued Interest
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Initiation of Phase I Trial of Oral Omecamtiv Indicative of AMGN''s Continued Interest
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
4Q11 and YE2011 Earnings: A Recap of Clinical Progress and Outlook for 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
4Q11 and YE2011 Earnings: A Recap of Clinical Progress and Outlook for 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Transfer of Coverage: Maintaining a Market Outperform Rating
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Transfer of Coverage: Maintaining a Market Outperform Rating
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
We are under review due to the departure from the firm of analyst
Provider: RODMAN & RENSHAW, CO.